{"id":5771,"date":"2006-02-11T23:45:09","date_gmt":"2006-02-11T22:45:09","guid":{"rendered":"http:\/\/moomango.co.uk\/htb\/?p=5771"},"modified":"2016-11-04T15:54:57","modified_gmt":"2016-11-04T15:54:57","slug":"10th-european-aids-conference-eacs-17-20-november-2005-dublin-ireland","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/5771","title":{"rendered":"10th European AIDS Conference (EACS), 17-20 November 2005, Dublin, Ireland"},"content":{"rendered":"<p><strong><a href=\"https:\/\/i-base.info\/htb\/keyword\/eacs-10th\">Reports from the conference<\/a>.<\/strong><\/p>\n<ul>\n<li><a title=\"Permanent link to Rifaximin cure reported for cryptosporidium in advanced HIV\" href=\"https:\/\/i-base.info\/htb\/5807\" rel=\"bookmark\">Rifaximin cure reported for cryptosporidium in advanced HIV<\/a><\/li>\n<li><a title=\"Permanent link to Analysis of hepatic events in 2NN study by CD4 entry criteria, levels differences between nevirapine and efavirenz; excess hepatic events in once-daily nevirapine arm linked to single site in Thailand\" href=\"https:\/\/i-base.info\/htb\/5804\" rel=\"bookmark\">Analysis of hepatic events in 2NN study by CD4 entry criteria, levels differences between nevirapine and efavirenz; excess hepatic events in once-daily nevirapine arm linked to single site in Thailand<\/a><\/li>\n<li><a title=\"Permanent link to FTC studies at EACS: reduced incidence of M184V compared to 3TC; side effect profile in clinical practice\" href=\"https:\/\/i-base.info\/htb\/5802\" rel=\"bookmark\">FTC studies at EACS: reduced incidence of M184V compared to 3TC; side effect profile in clinical practice<\/a><\/li>\n<li><a title=\"Permanent link to Paediatric studies at EACS: trends in antiretroviral use in the Madrid Cohort; life expectancy significantly increased HIV\/HCV co-infected children since HAART; use of tenofovir in treatment experienced children; switching to lopinavir\/r from double protease inhibitor regimen; once daily lopinavir\/r, 3TC and abacavir; planned treatment interruptions in children\" href=\"https:\/\/i-base.info\/htb\/5798\" rel=\"bookmark\">Paediatric studies at EACS: trends in antiretroviral use in the Madrid Cohort; life expectancy significantly increased HIV\/HCV co-infected children since HAART; use of tenofovir in treatment experienced children; switching to lopinavir\/r from double protease inhibitor regimen; once daily lopinavir\/r, 3TC and abacavir; planned treatment interruptions in children<\/a><\/li>\n<li><a title=\"Permanent link to Efficacy of lopinavir\/r in patients with advanced HIV (CD4 &lt;25 cells\/mm3)\" href=\"https:\/\/i-base.info\/htb\/8324\" rel=\"bookmark\">Efficacy of lopinavir\/r in patients with advanced HIV (CD4 &lt;25 cells\/mm3)<\/a><\/li>\n<li><a title=\"Permanent link to Potential barriers to use of T-20: results from patient and physician interviews\" href=\"https:\/\/i-base.info\/htb\/5796\" rel=\"bookmark\">Potential barriers to use of T-20: results from patient and physician interviews<\/a><\/li>\n<li><a title=\"Permanent link to Factors associated with sexual dysfunction in HIV patients\" href=\"https:\/\/i-base.info\/htb\/5793\" rel=\"bookmark\">Factors associated with sexual dysfunction in HIV patients<\/a><\/li>\n<li><a title=\"Permanent link to Decreased varicella zoster immunity in migrants from sub-Saharan Africa\" href=\"https:\/\/i-base.info\/htb\/5791\" rel=\"bookmark\">Decreased varicella zoster immunity in migrants from sub-Saharan Africa<\/a><\/li>\n<li><a title=\"Permanent link to Clinical experience of switching to atazanavir in the UK\u0092s largest clinic\" href=\"https:\/\/i-base.info\/htb\/5789\" rel=\"bookmark\">Clinical experience of switching to atazanavir in the UK\u0092s largest clinic<\/a><\/li>\n<li><a title=\"Permanent link to Replacing a PI with atazanavir: separating swans from ducklings?\" href=\"https:\/\/i-base.info\/htb\/5787\" rel=\"bookmark\">Replacing a PI with atazanavir: separating swans from ducklings?<\/a><\/li>\n<li><a title=\"Permanent link to TMC 125: some good and bad news\" href=\"https:\/\/i-base.info\/htb\/5784\" rel=\"bookmark\">TMC 125: some good and bad news<\/a><\/li>\n<li><a title=\"Permanent link to When to change a failing regimen: second-line and salvage strategies\" href=\"https:\/\/i-base.info\/htb\/5782\" rel=\"bookmark\">When to change a failing regimen: second-line and salvage strategies<\/a><\/li>\n<li><a title=\"Permanent link to Antiretrovirals and other stuff!\" href=\"https:\/\/i-base.info\/htb\/5779\" rel=\"bookmark\">Antiretrovirals and other stuff!<\/a><\/li>\n<li><a title=\"Permanent link to Heart disease in people with HIV\" href=\"https:\/\/i-base.info\/htb\/5776\" rel=\"bookmark\">Heart disease in people with HIV<\/a><\/li>\n<li><a title=\"Permanent link to Mortality trends: why people with HIV die (or don\u0092t) today\" href=\"https:\/\/i-base.info\/htb\/5773\" rel=\"bookmark\">Mortality trends: why people with HIV die (or don\u0092t) today<\/a><\/li>\n<\/ul>\n<p>The conference organisers have not yet published abstracts from the meeting online, although they will go online.<\/p>\n<p><em>[Note: abstracts have since been posted to the EACS abstract archive:\u00a0<a href=\"http:\/\/www.abstractserver.com\/eacsabstractarchive\">http:\/\/www.abstractserver.com\/eacsabstractarchive<\/a>]<\/em><\/p>\n\n<p>However, webcasts of several of the presentations are included, though free registration is required, and access is not instant:<\/p>\n<p>10th EUROPEAN AIDS CONFERENCE \/ EACS<\/p>\n<p><a href=\"http:\/\/www.eacs-conference2005.com\/\">http:\/\/www.eacs-conference2005.com<\/a><\/p>\n<p>The following subjects are covered in the reports from this conference:<\/p>\n<ul>\n<li>Rifaximin cure reported for cryptosporidium<\/li>\n<li>Analysis of hepatic events in 2NN study<\/li>\n<li>Efficacy of lopinavir\/r in patients with advanced HIV<\/li>\n<li>Potential barriers to use of T-20<\/li>\n<li>FTC studies at EACS<\/li>\n<li>Paediatric studies at EACS<\/li>\n<li>Factors associated with sexual dysfunction in HIV patients<\/li>\n<li>Decreased varicella zoster immunity in migrants from sub-Saharan Africa<\/li>\n<li>Clinical experience of switching to atazanavir<\/li>\n<li>TMC 125: some good and bad news<\/li>\n<li>Second-line and salvage strategies<\/li>\n<li>Antiretrovirals and other stuff!<\/li>\n<li>Heart disease in people with HIV<\/li>\n<li>Mortality trends: why people with HIV die (or don\u0092t) today<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Reports from the conference. Rifaximin cure reported for cryptosporidium in advanced HIV Analysis of hepatic events in 2NN study by CD4 entry criteria, levels differences between nevirapine and efavirenz; excess hepatic events in once-daily nevirapine arm linked to single site &hellip;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[12,70],"class_list":["post-5771","post","type-post","status-publish","format-standard","hentry","category-conference-reports","tag-conference-index","tag-eacs-10th-2005"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/5771","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=5771"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/5771\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=5771"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=5771"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=5771"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}